Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CERTAIN 2: Certolizumab Pegol in Rheumatoid Arthritis
NCT00843778Phase 3Completed
- Sponsor
- UCB
- Start
- Jan 2009
- Primary completion
- Dec 2012
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 5
01
Overview
Phase 3, open-label, single-arm trial of certolizumab pegol in rheumatoid arthritis (RA), sponsored by UCB. Primary endpoints: Treatment-emergent Adverse Events at 144 weeks and Treatment-emergent Serious Adverse Events at 144 weeks. Started Jan 2009; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00843778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00843778.